STAT1 and head and neck squamous cell carcinoma: Based on the finding that cetuximab resistance blunts the IFN-γ response by reducing STAT1 protein levels without genetic aberrations or transcriptional repression, we investigated the mechanism of reduced STAT1 protein in cetuximab-resistant HNSCC.